Moderna
MRNA
$133.32
-23.55%
Moderna is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, with a pipeline spanning infectious diseases, oncology, cardiovascular conditions, and rare genetic disorders. The company's COVID-19 vaccine validated its platform and established it as a leader in mRNA technology, though it now faces the challenge of transitioning to a multi-product commercial portfolio. Investor attention is currently focused on the FDA review of its mRNA flu vaccine, pipeline progress across 35 clinical candidates, and the path to profitability as COVID-19 revenues have declined sharply. The stock has been highly volatile, driven by regulatory catalysts and ongoing clinical data readouts, with debates centering on whether the current valuation adequately reflects the platform's long-term potential.…
MRNA
Moderna
$133.32
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating: Hold. Moderna is a promising but unproven growth story. The consensus recommendation is 'hold' with an average target price of $50.84, implying a -19.7% downside from the current price. While the FDA approval of the flu vaccine is a positive catalyst, the stock's recent surge (+137% over 1 year) may have already priced in much of the good news. The thesis is that the pipeline and new product launches will eventually drive profitability, but near-term losses and revenue volatility warrant caution.
Sign up to view all
MRNA 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock has strong momentum and a promising pipeline, but the valuation is stretched on trailing metrics and the analyst community is cautious. The key swing factor is the commercial success of the flu vaccine and the pace of pipeline progress. If revenue growth accelerates and losses narrow, the stance would upgrade to bullish. Conversely, if the flu vaccine disappoints or the company faces regulatory setbacks, the stance would turn bearish. The current price of $63.32 is above the average target, suggesting limited upside in the base case.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $89.33 and implied upside of -33.0% versus the current price.
Average Target
$89.33
0 analysts
Implied Upside
-33.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $170
Analyst target range
Moderna is covered by 19 analysts, with a consensus recommendation of 'hold' and a mean recommendation score of 2.91 (where 1 is strong buy and 5 is sell). The average target price is $50.84, which implies a downside of -19.7% from the current price of $63.32. The distribution of ratings includes a mix of hold, overweight, and underperform, with recent actions from major firms such as Morgan Stanley (Equal Weight), B of A Securities (Underperform), and RBC Capital (Sector Perform) indicating a cautious stance.
Bulls vs Bears: MRNA Investment Factors
Moderna presents a classic high-risk, high-reward biotech investment. The bull case rests on the successful FDA approval of the flu vaccine, a deep pipeline, and a strong balance sheet, which could drive substantial revenue growth and a re-rating. However, the bear case is equally compelling: persistent losses, volatile revenue, and a consensus target implying a 20% downside suggest the market may have already priced in much of the optimism. Currently, the bearish evidence is slightly stronger due to the negative analyst sentiment and the lack of near-term profitability, but the FDA win and pipeline progress provide tangible upside catalysts. The central tension is whether the flu vaccine and other pipeline products can generate enough revenue to offset COVID declines and justify the current valuation, or whether the stock will correct to reflect the ongoing losses.
Bullish
- Powerful 1-Year Momentum: MRNA surged 137.2% over the past year, vastly outperforming the S&P 500's +20.4% gain. This demonstrates strong investor conviction in the company's pipeline and strategic direction, with relative strength of +116.9% over the same period.
- FDA Flu Vaccine Approval Catalyst: The FDA's recent approval of Moderna's mRNA flu vaccine (reported June 30, 2026) provides a major new revenue stream. This is the first non-COVID product to reach the market, validating the platform's versatility and reducing reliance on COVID-19 sales.
- Deep Pipeline with 35 Candidates: Moderna has 35 mRNA development candidates in clinical studies, spanning infectious disease, oncology, cardiovascular, and rare genetic diseases. This diversification mitigates single-product risk and offers multiple shots on goal for future blockbusters.
- Strong Balance Sheet with Low Debt: The company maintains a current ratio of 3.29 and a debt-to-equity ratio of just 0.22, indicating ample liquidity to fund operations. This financial flexibility supports continued R&D investment without immediate solvency concerns.
Bearish
- Analyst Consensus is Hold with Downside: The average analyst target price is $50.84, implying a -19.7% downside from the current price of $63.32. With a mean recommendation score of 2.91 (hold), the sell-side is cautious, and recent actions from major banks like B of A (Underperform) reinforce this skepticism.
- Persistent Losses and Negative Margins: Moderna reported a net loss of $1.34 billion in Q1 2026, with a net margin of -345%. The company has been unprofitable for several quarters, and the negative operating margin of -158% indicates heavy spending on R&D and commercialization that has yet to yield profits.
- Revenue Volatility and COVID Decline: Quarterly revenue has swung dramatically: $142M (Q2 2025), $1.016B (Q3 2025), $678M (Q4 2025), and $389M (Q1 2026). This instability reflects the fading COVID-19 franchise and the uncertainty of new product uptake, making forecasting difficult.
- High Valuation on Trailing Metrics: The trailing PS ratio of 5.9x is elevated for a company with declining revenues and negative earnings. Even the EV-to-sales of 9.7x suggests the market is pricing in significant future growth, leaving little room for disappointment.
MRNA Technical Analysis
Moderna's stock has been in a powerful uptrend over the past year, with a 1-year price change of +137.2%, dramatically outperforming the S&P 500's +20.4% gain. The current price of $63.32 sits at 68.4% of the 52-week range (between $22.28 low and $85.60 high), indicating the stock has recovered strongly from its lows but remains below its peak. This positioning suggests a market that is optimistic about the company's pipeline but cautious about near-term execution, as the stock trades well off its highs despite the strong annual performance.
Beta
0.90
0.90x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$177
Price range past year
Annual Return
+395.8%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | +123.5% | +1.9% |
| 3m | +184.4% | +2.3% |
| 6m | +167.3% | +10.6% |
| 1y | +395.8% | +19.5% |
| ytd | +332.0% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Moderna's revenue trajectory has been highly volatile, with Q1 2026 revenue of $389 million representing a 2.6% year-over-year increase, but this follows a pattern of dramatic swings: Q2 2025 revenue was just $142 million, Q3 2025 jumped to $1.016 billion, and Q4 2025 fell to $678 million. The company's reliance on COVID-19 vaccine sales has diminished, and the recent quarter's growth is modest, indicating that new product launches are not yet offsetting the decline in COVID-19 revenues. The multi-quarter trend shows extreme variability, making it difficult to discern a clear growth trajectory, but the company is clearly in a transition phase as it seeks to commercialize its broader pipeline.
Quarterly Revenue
$389000000.0B
2026-03
Revenue YoY Growth
+263.6%
YoY Comparison
Gross Margin
-145.5%
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given that Moderna's net income is negative (EPS of -$0.25 in the most recent quarter), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio of 5.9x is based on trailing twelve-month revenue, while the forward PS ratio (using estimated revenue of $6.85 billion) is approximately 1.7x, implying that the market expects significant revenue growth in the coming year. The gap between trailing and forward PS ratios suggests that investors are pricing in a substantial revenue ramp, likely driven by the launch of the flu vaccine and other pipeline products.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Moderna's financial health is under pressure from heavy R&D spending and negative margins. In Q1 2026, the company reported a net loss of $1.34 billion, with an operating margin of -158% and a gross margin of -145.5%, indicating that cost of revenue exceeded sales. The negative free cash flow of -$1.58 billion (TTM) suggests the company is burning through cash, though the current ratio of 3.29 and low debt-to-equity of 0.22 provide a cushion. Revenue concentration is a major risk: COVID-19 vaccine sales have declined sharply, and the new flu vaccine is still ramping up, making the revenue base highly volatile (quarterly swings from $142M to $1.016B). This volatility complicates financial planning and could lead to further losses if new products fail to gain traction.
FAQ
The key risks are: (1) Financial risk: The company is burning cash with a negative free cash flow of -$1.58B (TTM) and a net loss of $1.34B in Q1 2026. While the balance sheet is strong, prolonged losses could lead to dilution. (2) Competitive risk: The vaccine market is highly competitive, with Pfizer, BioNTech, and Novavax, and the flu vaccine faces entrenched players. (3) Regulatory risk: Any safety issues or manufacturing problems with the flu vaccine could lead to recalls or restrictions. (4) Market risk: The stock is volatile (beta 0.899, 1-month change -7.3%) and could be affected by sector rotation or macro headwinds. The most severe risk is a pipeline failure, which could send the stock to the 52-week low of $22.28, a -64.8% decline.
The 12-month forecast is mixed. In the base case (50% probability), the stock trades in a range of $50-$65, with the average analyst target of $50.84 as a potential downside. In the bull case (25% probability), the stock could reach $70-$85, driven by strong flu vaccine sales and pipeline progress. In the bear case (25% probability), the stock could fall to $25-$40, if the flu vaccine disappoints or pipeline setbacks occur. The most likely scenario is the base case, where the company makes progress but remains unprofitable, leading to a sideways or slightly lower stock price. The key assumption is that the flu vaccine ramps up gradually, but not enough to offset COVID declines entirely.
Based on trailing metrics, MRNA appears overvalued: the PS ratio is 5.9x, and the EV-to-sales is 9.7x, which are high for a company with declining revenues and negative earnings. However, on a forward basis, the PS ratio is ~1.7x, implying the market expects revenue to grow to $6.85B in the next year. This suggests the stock is priced for significant growth, and if that growth materializes, it could be fairly valued. Compared to peers, the forward PS is not excessive, but the lack of profitability and the high uncertainty make it difficult to justify the current price. The market is pricing in a successful transition to a multi-product company, which is not yet guaranteed. Therefore, the stock is neither clearly overvalued nor undervalued; it is a bet on future execution.
MRNA is not a clear 'buy' at current levels. The average analyst target of $50.84 implies a -19.7% downside, and the consensus is a 'hold'. While the FDA approval of the flu vaccine is a positive catalyst, the stock has already rallied 137% over the past year, suggesting much of the good news is priced in. The company is still loss-making, with a net margin of -345% in Q1 2026, and revenue is volatile. However, for investors with a high risk tolerance and a long-term horizon, the pipeline offers significant upside potential. A better entry point might be below $50, where the risk/reward is more favorable. Ultimately, it is a good buy only if you believe the flu vaccine and other pipeline products will drive substantial revenue growth and lead to profitability by 2028.
MRNA is more suitable for long-term investment, given its high volatility and the time required for pipeline development. The stock has a beta of 0.899, but its 1-month change of -7.3% and max drawdown of -35.5% indicate significant short-term risk. For long-term investors, the potential for the mRNA platform to generate multiple blockbusters could provide substantial returns over 5-10 years. However, short-term trading is risky due to binary events like FDA decisions and clinical data readouts. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature and the company to achieve profitability. The company does not pay a dividend, so returns depend entirely on capital appreciation, which is uncertain. Therefore, only investors with a high risk tolerance and a long time horizon should consider MRNA.